Rick Doblin on the future of psychedelic-assisted therapy, MDMA research, PTSD treatment, harm reduction, and drug policy

Rick Doblin discusses how psychedelic-assisted psychotherapy could expand mental health treatment and contribute to broader social healing. He explains the contrast between classic psychedelics, which he describes as ego-dissolving, and MDMA, which may reduce fear and increase emotional openness in therapy. The conversation focuses on MAPS clinical trials of MDMA-assisted psychotherapy for chronic PTSD, including treatment structure, therapist training, two-therapist teams, preparation and integration, and reported phase two outcomes. Doblin also addresses research involving social anxiety, life-threatening illness, alcohol use, couples therapy, and possible future applications. He describes psychedelic harm reduction through the Zendo Project, group and community-based models, drug policy reform, and MAPS's nonprofit and public benefit corporation structure. The discussion presents therapeutic potential alongside the need for ethical standards, regulatory approval, trained clinicians, and safer legal contexts.